Skin Cancer Clinical Trial
Official title:
A Safety and Efficacy Study of Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
Status | Recruiting |
Enrollment | 39 |
Est. completion date | January 1, 2026 |
Est. primary completion date | January 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subjects with histopathological confirmation of either recurrent or persistent disease following DaRT treatment. - Subjects with a tumor size = 5 centimeters in the longest diameter. - Target lesion technically amenable for full coverage with the Alpha DaRT seeds. - Brachytherapy indication validated by a multidisciplinary team. - Measurable disease according to RECIST v1.1. - Subjects over 18 years old. - Subjects' ECOG Performance Status Scale is < 2. - Subjects' life expectancy is more than 6 months. - Platelet count =100,000/mm3. - AST and ALT = 2.5 X ULN - WBC = 3500/µl, granulocyte = 1500/µl - International normalized ratio of prothrombin time =1.4 for patients not on Warfarin - Creatinine =2.3 mg/dL. - Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test before the Ra-224 implantation and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after brachytherapy. - Subjects are willing to sign an informed consent form. Exclusion Criteria: - Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids - Known hypersensitivity to any of the components of the treatment. - Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months. - Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial or interfere with the study endpoints. - Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. - Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy. - Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT - High probability of protocol non-compliance (in opinion of investigator) - Subjects not willing to sign an informed consent - Women who are pregnant or breastfeeding. |
Country | Name | City | State |
---|---|---|---|
Israel | Sharett institute, Hadassah University Hospital - Ein-Kerem | Jerusalem |
Lead Sponsor | Collaborator |
---|---|
Alpha Tau Medical LTD. |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Adverse Events | Incidence of all Adverse Events (AE) related and unrelated to the study treatment. | From conscent up to 9-11 weeks post DaRT insertion | |
Primary | Tumor response to DaRT | Assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1) | 9-11 weeks post DaRT insertion | |
Primary | Adverse events | Frequency, severity and causality of acute adverse events related to the DaRT treatment. Adverse events will be assessed and graded according to Common Terminology and Criteria for adverse events (CTCAE) version 5.0. | From conscent up to 9-11 weeks post DaRT insertion | |
Secondary | Change in tumor volume | Based on imaging | 9-11 weeks post DaRT insertion | |
Secondary | Local control rate | Will be assessed as the number of complete responses, partial responses and stable disease divided by the total numbers of tumors treated. | 9-11 weeks post DaRT insertion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
Completed |
NCT03740815 -
Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection
|
N/A | |
Recruiting |
NCT05779423 -
Cryoablation+Ipilimumab+Nivolumab in Melanoma
|
Phase 2 | |
Terminated |
NCT01468818 -
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT01820234 -
Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event
|
N/A | |
Completed |
NCT00535769 -
Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use
|
Phase 0 | |
Completed |
NCT00526032 -
Melanoma Detection by Oblique-Incidence Optical Spectroscopy
|
N/A | |
Completed |
NCT00588341 -
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
|
Phase 2 | |
Active, not recruiting |
NCT01447199 -
The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)
|
||
Enrolling by invitation |
NCT04758988 -
AI Augmented Training for Skin Specialists
|
N/A | |
Not yet recruiting |
NCT04534868 -
Patient Acceptance And Satisfaction of Teledermoscopy In General Practice In a Belgian Rural Area
|
N/A | |
Recruiting |
NCT04138342 -
Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer
|
Phase 1 | |
Completed |
NCT03673917 -
Cosmetology Students and Skin Cancer
|
N/A | |
Recruiting |
NCT04341064 -
Sun-safe Habits Intervention and Education
|
Phase 3 | |
Completed |
NCT04206995 -
Cancer Sensing: Evaluation of Odour Sampling Techniques
|
||
Recruiting |
NCT05574101 -
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05860881 -
Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)
|
Phase 3 | |
Completed |
NCT05146622 -
Virtual Sun Safe Workplaces Ph I
|
||
Recruiting |
NCT05068310 -
Applicability of a Cellular Resolution Full-field OCT Image System for Pigmented and Non-pigmented Skin Tumors
|
||
Recruiting |
NCT03889899 -
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
|
N/A |